• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Does Niraparib Treatment Increase Survival for Those with Newly Diagnosed Ovarian Cancer?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Up to 85% of women with advanced ovarian cancer will have a recurrence
  • Niraparib is a PARP inhibitor used for maintenance therapy after platinum-based chemotherapy
  • Efficacy of niraparib for newly diagnosed advanced ovarian cancer is unknown
  • González-Martín et al. (NEJM, 2019) studied the efficacy and safety of niraparib therapy after platinum-based chemotherapy for patients with newly diagnosed advanced ovarian cancer at high risk for relapse

METHODS:

  • Randomized, double-blind, phase 3 trial (RCT)
  • Participants
    • Newly diagnosed advanced ovarian cancer
  • Patients random assigned (2:1) into either
    • Intervention: Niraparib once daily after a response to platinum-based chemotherapy
    • Control: Placebo once daily after a response to platinum-based chemotherapy
  • Primary outcome: Progression-free survival among
    • Patients who had tumors with homologous-recombination deficiency (pathogenic variants in BRCA genes or structural chromosomal alterations or other genomic changes that would indicate abnormal repair mechanisms)
    • Overall population
  • Secondary outcome: Overall survival

RESULTS:

  • 733 patients randomized | 50.9% had tumors with homologous-recombination deficiency
  • Patients that had tumors with homologous-recombination deficiency: Median progression-free survival was significantly longer in the niraparib group (P<0.001)
    • Niraparib: 21.9 months
    • Placebo: 10.4 months
    • Hazard ratio (HR) for disease progression or death: 0.43 (95% CI, 0.31 to 0.59)
  • Overall population: Progression-free survival was also significantly longer in the niraparib group (P<0.001)
    • Niraparib:13.8 months
    • Placebo: 8.2 months
    • HR for disease progression or death: 0.62 (95% CI, 0.50 to 0.76)
  • Overall survival at 24-month interim analysis
    • Niraparib: 84% 
    • Placebo: 77%
    • HR 0.70 (95% CI, 0.44 to 1.11)
  • The most common significant adverse events (≥ grade 3)
    • Anemia: 31%
    • Thrombocytopenia: 28.7%
    • Neutropenia: 12.8%
    • No deaths reported

CONCLUSION:

  • Following response to platinum-based chemotherapy, niraparib treatment resulted in significantly longer progression-free survival vs placebo in patients with newly diagnosed ovarian cancer
  • The presence or absence of homologous-recombination deficiency did no impact these results
  • The authors also state that

…overall survival may also be improved, but the data are not sufficiently mature to assess this end point with precision

Learn More – Primary Sources:

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Try it Free  »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Do Contraceptives Decrease Risk for All Ovarian Cancers?
BRCA1 & BRCA2 Mutations: What Are the Risks for Developing Breast and Ovarian Cancer?
Olaparib – A New Targeted Maintenance Therapy for Advanced Ovarian Cancer?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site